Pfizer divests USD 3.5 billion stake in Haleon
Sensodyne-marker Haleon has said that Pfizer, its top shareholder, divested approximately a $3.5 billion stake in the consumer healthcare firm, reducing its ownership in the British company to 22.6%. Previously, Pfizer held a 32% stake, while the second-largest shareholder, GSK, held a 4.2% stake.
This marks Pfizer's first stake sale in Haleon since the company's inception in 2022, following its spin-off from GSK and subsequent listing. Last year, Pfizer announced its intention to gradually decrease its ownership in a "slow and methodical" manner over the course of months.
Meanwhile, GSK, which initially held a 12.9% stake, has been reducing its stake over the past year, with the most recent sale occurring in January.
In terms of numbers, Pfizer sold 594 million shares at a price of £3.08 apiece and approximately 196.5 million American Depository Shares (ADS) at $7.85 each, totaling around $3.1 billion. This figure is higher than the 630 million share sale disclosed by Haleon on Monday. Additionally, Haleon announced plans to repurchase £315 million ($399.92 million) worth of shares from Pfizer through an off-market transaction.
Read also: GSK raises USD 1.24 billion from latest Haleon stake sale
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.